

ASX Announcement
20 April 2026

Director Appointment

The Directors of Tissue Repair Limited (ASX: TRP) (“**TRP**” or “**the Company**”) are pleased to announce the appointment of Mr Peter Scutt as an Executive Director to the Board, effective today. Mr Scutt has executed a consultancy agreement with the Company to support the CEO in relation to overall strategy for both onshore and offshore market entry, development and distribution of TR Pro+ and additional products in the aesthetic and medical markets.

Brief profile of Peter Scutt

Mr Scutt is a Co-Founder and former Director of Tissue Repair, who alongside Mr Tony Charara, was previously involved in progressing the clinical development of its novel and proprietary active ingredient for wound healing. He is also a Co-Founder and Non-Executive Director of Mable Technologies Pty Limited, having previously been its CEO. He has previously been a Director of Novogen, who’s US subsidiary was an oncology company focussed on the clinical development of novel cancer therapies. He has been a founder and managing partner of a US Venture Capital fund and early in his career, was a Partner and Senior Managing Director of Bankers Trust Company, NY where he also sat on the Boards of BT Securities Corporation and BT Futures Corporation.

TRP’s CEO, Tony Charara said he was pleased to welcome Peter Scutt to the Board.

Key Terms of Consultancy Agreement -Peter Scutt	
Commencement Date	20 February 2026
Fees	Flat rate contract is \$10,500 plus GST (if applicable) per month for 3 days per week
Termination	Until 20 February 2027

For further information in relation to this release please contact Sushma Kejriwal at s.kejriwal@acclime.com.

This announcement has been approved for release by the Board of the Company.

-ENDS-